Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 433

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer

Wong, Sandra L., Mangu, Pamela B., Choti, Michael A., Crocenzi, Todd S., Dodd, Gerald D., Dorfman, Gary S., Eng, Cathy, Fong, Yuman, Giusti, Andrew F., Lu, David, Marsland, Thomas A., Michelson, Rob, Poston, Graeme J., Schrag, Deborah, Seidenfeld, Jerome, Benson, Al B.·2010·Journal of Clinical Oncology

Abstract

Purpose: To review the evidence about the efficacy and utility of radiofrequency ablation (RFA) for hepatic metastases from colorectal cancer (CRHM). Methods: The American Society of Clinical Oncology (ASCO) convened a panel to conduct and analyze a comprehensive systematic review of the RFA literature from Medline and the Cochrane Collaboration Library. Results: Because data were considered insufficient to form the basis of a practice guideline, ASCO has instead published a clinical evidence review. The evidence is from single-arm, retrospective, and prospective trials. No randomized controlled trials have been included. The following three clinical issues were considered by the panel: the efficacy of surgical hepatic resection versus RFA for resectable tumors; the utility of RFA for unresectable tumors; and RFA approaches (open, laparoscopic, or percutaneous). Evidence suggests that hepatic resection improves overall survival (OS), particularly for patients with resectable tumors without extrahepatic disease. Careful patient and tumor selection is discussed at length in the literature. RFA investigators report a wide variability in the 5-year survival rate (14% to 55%) and local tumor recurrence rate (3.6% to 60%). The reported mortality rate was low (0% to 2%), and the major complications rate was commonly reported to be between 6% and 9%. RFA is currently performed with all three approaches. Conclusion: There is a compelling need for more research to determine the efficacy and utility of RFA to increase local recurrence-free, progression-free, and disease-free survival as well as OS for patients with CRHM. Clinical trials have established that hepatic resection can improve OS for patients with resectable CRHM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.4450

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 433

Metadata

Authors
Wong, S. L., Mangu, P. B., Choti, M. A., Crocenzi, T. S., Dodd, G. D., Dorfman, G. S., Eng, C., Fong, Y., Giusti, A. F., Lu, D., Marsland, T. A., Michelson, R., Poston, G. J., Schrag, D., Seidenfeld, J., & Benson, A. B.
Venue
Journal of Clinical Oncology
Published
2010-01-20
Volume
28
Issue
3
Pages
493-508
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2120502230
Cited by
433
References
67
FWCI
20.54
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer. https://app.cochat.ai/papers/10.1200/jco.2009.23.4450
The paper
Wong, S. L., Mangu, P. B., Choti, M. A., Crocenzi, T. S., Dodd, G. D., Dorfman, G. S., Eng, C., Fong, Y., Giusti, A. F., Lu, D., Marsland, T. A., Michelson, R., Poston, G. J., Schrag, D., Seidenfeld, J., & Benson, A. B. (2010). American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.23.4450

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.